688553 汇宇制药
已收盘 02-09 15:00:01
资讯
新帖
简况
每周股票复盘:汇宇制药(688553)2025年预亏2400万至2900万元
证券之星 · 02-01
每周股票复盘:汇宇制药(688553)2025年预亏2400万至2900万元
汇宇制药:预计2025年全年营业收入9.6亿元至10.9亿元
证券之星 · 01-29
汇宇制药:预计2025年全年营业收入9.6亿元至10.9亿元
破发股汇宇制药二股东拟被动减持 2021年上市募24.7亿
中金财经 · 01-29
破发股汇宇制药二股东拟被动减持 2021年上市募24.7亿
汇宇制药(688553.SH)发预亏,预计2025年归母净亏损2400万元至2900万元
智通财经 · 01-29
汇宇制药(688553.SH)发预亏,预计2025年归母净亏损2400万元至2900万元
汇宇制药(688553)披露持股5%以上股东被动减持股份计划公告,1月28日股价下跌2.86%
证券之星 · 01-28
汇宇制药(688553)披露持股5%以上股东被动减持股份计划公告,1月28日股价下跌2.86%
每周股票复盘:汇宇制药(688553)股东减持33.94万股
证券之星 · 01-25
每周股票复盘:汇宇制药(688553)股东减持33.94万股
1月21日汇宇制药发布公告,股东减持33.94万股
证券之星 · 01-21
1月21日汇宇制药发布公告,股东减持33.94万股
每周股票复盘:汇宇制药(688553)与阿斯利康开展临床合作
证券之星 · 01-11
每周股票复盘:汇宇制药(688553)与阿斯利康开展临床合作
汇宇制药(688553)披露与阿斯利康达成临床研究合作,1月9日股价上涨6.8%
中金财经 · 01-10
汇宇制药(688553)披露与阿斯利康达成临床研究合作,1月9日股价上涨6.8%
汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作
智通财经 · 01-09
汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作
1月9日汇宇制药涨6.80%,创金合信医疗保健股票A基金重仓该股
中金财经 · 01-09
1月9日汇宇制药涨6.80%,创金合信医疗保健股票A基金重仓该股
1月8日汇宇制药涨5.42%,创金合信医疗保健股票A基金重仓该股
证券之星 · 01-08
1月8日汇宇制药涨5.42%,创金合信医疗保健股票A基金重仓该股
每周股票复盘:汇宇制药(688553)西咪替丁注射液获注册证书
证券之星 · 2025-12-28
每周股票复盘:汇宇制药(688553)西咪替丁注射液获注册证书
汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书
智通财经 · 2025-12-23
汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书
汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可
智通财经 · 2025-12-19
汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可
汇宇制药:盐酸尼卡地平注射液获得药品注册证书
证券之星 · 2025-12-12
汇宇制药:盐酸尼卡地平注射液获得药品注册证书
汇宇制药(688553)披露持股5%以上股东股份被轮候冻结的公告,12月11日股价下跌1.17%
证券之星 · 2025-12-11
汇宇制药(688553)披露持股5%以上股东股份被轮候冻结的公告,12月11日股价下跌1.17%
汇宇制药(688553.SH)拟出资1.5亿元参与设立私募基金
智通财经 · 2025-11-27
汇宇制药(688553.SH)拟出资1.5亿元参与设立私募基金
汇宇制药涨5.37%,开源证券二个月前给出“买入”评级
证券之星 · 2025-11-24
汇宇制药涨5.37%,开源证券二个月前给出“买入”评级
每周股票复盘:汇宇制药(688553)多款产品获境外上市许可
证券之星 · 2025-11-23
每周股票复盘:汇宇制药(688553)多款产品获境外上市许可
加载更多
公司概况
公司名称:
四川汇宇制药股份有限公司
所属行业:
医药制造业
上市日期:
2021-10-26
主营业务:
四川汇宇制药股份有限公司的主营业务是肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。公司的主要产品是原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。
发行价格:
38.87
{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":19.52,"timestamp":1770620401000,"preClose":19.25,"halted":0,"volume":4319433,"delay":0,"changeRate":0.014,"floatShares":344000000,"shares":424000000,"eps":0.1116,"marketStatus":"已收盘","change":0.27,"latestTime":"02-09 15:00:01","open":19.48,"high":19.69,"low":19.35,"amount":84393300,"amplitude":0.0177,"askPrice":19.52,"askSize":248,"bidPrice":19.51,"bidSize":112,"shortable":0,"etf":0,"ttmEps":0.1116,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":19.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":21.18,"lowLimit":17.33,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"isCdr":false,"pbRate":2.22,"roa":"--","peRate":174.910394,"roe":"--","epsLYR":0.77,"committee":0.308007,"marketValue":8269000000,"turnoverRate":0.0126,"status":0,"afterMarket":{"amount":0,"volume":0,"close":19.52,"buyVolume":0,"sellVolume":0,"time":1770622437558,"indexStatus":"已收盘 02-09 15:30:00","preClose":19.25},"floatMarketCap":6706000000},"requestUrl":"/m/hq/s/688553","defaultTab":"news","newsList":[{"id":"2608789077","title":"每周股票复盘:汇宇制药(688553)2025年预亏2400万至2900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608789077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608789077?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:28","pubTimestamp":1769887692,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,汇宇制药报收于19.19元,较上周的20.73元下跌7.43%。本周,汇宇制药1月26日盘中最高价报20.84元。业绩披露要点汇宇制药发布业绩预告,预计2025年全年扣非后净利润盈利7800万元至9300万元。预计2025年全年归属净利润亏损2400万元至2900万元。2025年度营业收入预计同比下降12.28%至0.40%;归属于母公司所有者的净利润同比下降108.91%至107.38%;扣除非经常性损益的净利润同比下降15.33%至增长0.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2607704418","title":"汇宇制药:预计2025年全年营业收入9.6亿元至10.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704418","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704418?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:48","pubTimestamp":1769676507,"startTime":"0","endTime":"0","summary":"证券之星消息,汇宇制药发布业绩预告,预计2025年全年营业收入9.6亿元至10.9亿元。汇宇制药2025年三季报显示,前三季度公司主营收入7.42亿元,同比下降12.92%;归母净利润-5080.47万元,同比下降122.35%;扣非净利润7956.06万元,同比下降20.62%;其中2025年第三季度,公司单季度主营收入2.89亿元,同比下降9.7%;单季度归母净利润2991.58万元,同比下降81.55%;单季度扣非净利润3148.74万元,同比下降44.89%;负债率23.69%,投资收益333.21万元,财务费用-3254.8万元,毛利率80.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900027336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553"],"gpt_icon":0},{"id":"2607670143","title":"破发股汇宇制药二股东拟被动减持 2021年上市募24.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2607670143","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607670143?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:28","pubTimestamp":1769675286,"startTime":"0","endTime":"0","summary":"中国经济网北京1月29日讯 汇宇制药 昨日晚间披露《持股5%以上股东被动减持股份计划公告》。 截至公告披露日,黄干益持有汇宇制药股份数量为27,219,439股,占公司总股本的6.426%,上述股份来源于公司首次公开发行前取得的股份,且上述股份已被司法冻结,全部为无限售流通股。 汇宇制药发行费用合计1.11亿元,其中中信建投证券、国都证券获得承销费9887.48万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260129/31982852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2607706235","title":"汇宇制药(688553.SH)发预亏,预计2025年归母净亏损2400万元至2900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607706235","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607706235?lang=zh_cn&edition=full","pubTime":"2026-01-29 15:43","pubTimestamp":1769672626,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)披露2025年年度业绩预亏公告,公司预计2025年度实现归属于母公司所有者的净亏损2400万元至2900万元;预计2025年度实现归属于母公司所有者的扣除非经常性损益的净利润为7800万元至9300万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"汇宇制药(688553.SH)发预亏,预计2025年归母净亏损2400万元至2900万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2606717110","title":"汇宇制药(688553)披露持股5%以上股东被动减持股份计划公告,1月28日股价下跌2.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717110","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717110?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:32","pubTimestamp":1769610738,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘,汇宇制药报收于19.69元,较前一交易日下跌2.86%,最新总市值为83.41亿元。近日,汇宇制药披露《持股5%以上股东被动减持股份计划公告》。公告显示,截至公告披露日,公司股东黄干益持有公司27,219,439股,占总股本的6.426%,股份来源于首次公开发行前取得,且已被司法冻结。本次减持为被动减持,不影响公司治理结构和持续经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2606232511","title":"每周股票复盘:汇宇制药(688553)股东减持33.94万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232511","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232511?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:28","pubTimestamp":1769279292,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,汇宇制药报收于20.73元,较上周的21.0元下跌1.29%。本周,汇宇制药1月19日盘中最高价报21.18元。股本股东变化股东增减持1月21日汇宇制药发布公告,股东王晓鹏于2025年10月24日至2026年1月21日合计减持33.94万股,占公司目前总股本的0.0801%。减持后持股数量为16,698,125股,持股比例降至3.942%。会议认为该关联交易属正常商业行为,定价公平合理,符合监管要求,未损害公司及股东尤其是中小股东利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2605010864","title":"1月21日汇宇制药发布公告,股东减持33.94万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2605010864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605010864?lang=zh_cn&edition=full","pubTime":"2026-01-21 18:01","pubTimestamp":1768989674,"startTime":"0","endTime":"0","summary":"证券之星消息,1月21日汇宇制药发布公告《汇宇制药:股东减持股份结果公告》,其股东王晓鹏于2025年10月24日至2026年1月21日间合计减持33.94万股,占公司目前总股本的0.0801%,变动期间该股股价下跌2.11%,截止1月21日收盘报20.83元。股东增减持详情见下表:根据汇宇制药2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100030386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2602535649","title":"每周股票复盘:汇宇制药(688553)与阿斯利康开展临床合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535649","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535649?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:49","pubTimestamp":1768070947,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,汇宇制药报收于22.0元,较上周的17.79元上涨23.66%。本周,汇宇制药1月9日盘中最高价报22.1元。汇宇制药当前最新总市值93.19亿元,在化学制药板块市值排名61/150,在两市A股市值排名2149/5182。本周关注点公司公告汇总:汇宇制药子公司与阿斯利康签署临床试验合作协议,推进HYP-6589片联合奥希替尼治疗非小细胞肺癌的研究。本次合作不构成重大资产重组,无需提交公司董事会或股东会审议,预计不会对公司财务状况和经营成果产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2602002463","title":"汇宇制药(688553)披露与阿斯利康达成临床研究合作,1月9日股价上涨6.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602002463","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602002463?lang=zh_cn&edition=full","pubTime":"2026-01-10 08:55","pubTimestamp":1768006559,"startTime":"0","endTime":"0","summary":"公司近日发布公告称,其全资子公司汇宇海玥与阿斯利康签署《临床试验合作协议》,就自主研发的I类创新药HYP-6589片与阿斯利康的奥希替尼联合治疗特定类型非小细胞肺癌的临床研究展开合作。本次合作不构成重大资产重组,无需提交公司董事会或股东会审议,预计不会对公司财务状况和经营成果产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260110/31931449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1829250122.USD","BK4568","LU2456880835.USD","BK4585","BK0239","LU0109394709.USD","BK4588","LU2462157665.USD","LU2417539215.USD","AZN","688553","BK4007","LU0889565916.HKD","LU2236285917.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602323004","title":"汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602323004","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602323004?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:27","pubTimestamp":1767947265,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药 发布公告,公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片是一种高选择性SOS1小分子抑制剂。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》,就HYP-6589片与奥希替尼临床联合用药研究展开合作。公司与阿斯利康达成临床研究合作,合作双方共同探索公司自主研发的化学药I类创新药HYP-6589片与阿斯利康奥希替尼联合治疗特定类型非小细胞肺癌的疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU0889565916.HKD","BK0239","BK4588","LU2236285917.USD","LU2462157665.USD","LU2456880835.USD","LU1829250122.USD","LU2417539215.USD","BK4568","BK4585","LU0109394709.USD","688553","BK4007","AZN"],"gpt_icon":0},{"id":"2602032332","title":"1月9日汇宇制药涨6.80%,创金合信医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602032332","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602032332?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:54","pubTimestamp":1767945242,"startTime":"0","endTime":"0","summary":"证券之星消息,1月9日汇宇制药涨6.80%,收盘报22.0元,换手率4.32%,成交量14.85万手,成交额3.16亿元。重仓汇宇制药的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为创金合信基金的创金合信医疗保健股票A。创金合信医疗保健股票A目前规模为1.92亿元,最新净值2.119,较上一交易日下跌0.24%,近一年上涨45.7%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/09/20260109785284.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/09/20260109785284.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260109/31929461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2601356682","title":"1月8日汇宇制药涨5.42%,创金合信医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356682","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356682?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:36","pubTimestamp":1767857774,"startTime":"0","endTime":"0","summary":"证券之星消息,1月8日汇宇制药涨5.42%,收盘报20.6元,换手率4.34%,成交量14.91万手,成交额3.08亿元。重仓汇宇制药的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为创金合信基金的创金合信医疗保健股票A。创金合信医疗保健股票A目前规模为1.92亿元,最新净值2.124,较上一交易日上涨4.01%,近一年上涨44.98%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2594479244","title":"每周股票复盘:汇宇制药(688553)西咪替丁注射液获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594479244","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594479244?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:01","pubTimestamp":1766862074,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,汇宇制药报收于17.88元,较上周的18.64元下跌4.08%。本周关注点公司公告汇总:西咪替丁注射液获得药品注册证书,视同通过仿制药一致性评价。公司公告汇总自愿披露西咪替丁注射液获得药品注册证书的公告四川汇宇制药股份有限公司近日收到国家药品监督管理局核准签发的西咪替丁注射液《药品注册证书》,该产品注册分类为化学药品3类,视同通过仿制药质量和疗效一致性评价。西咪替丁注射液主要用于治疗消化道溃疡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2593546738","title":"汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593546738","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593546738?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:34","pubTimestamp":1766475255,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司于近日收到国家药品监督管理局核准签发的公司产品西咪替丁注射液的《药品注册证书》,西咪替丁注射液主要适应症为消化道溃疡。公司获批的西咪替丁注射液注册分类为化学药品3类,按照与参比制剂质量和疗效一致的技术要求审评并获批,批准后视同通过仿制药质量和疗效一致性评价。根据国家相关政策,通过一致性评价的药品品种在医保支付及医疗机构采购等领域将获得更大的支持力度。公司研发的西咪替丁注射液通过仿制药一致性评价,提升了自身的竞争能力,对公司的发展起到积极作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2592159532","title":"汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2592159532","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592159532?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:41","pubTimestamp":1766130101,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司子公司Seacross (Europe) Pharma Ltd.于近期分别收到意大利药品管理局和挪威药品管理局核准签发的公司产品注射用紫杉醇(白蛋白结合型)的上市许可。公司研发的注射用紫杉醇(白蛋白结合型)分别获得意大利、挪威的上市许可,有利于公司在国际市场产品管线的丰富,提升市场的品牌形象,持续拓展国际业务的广度和深度,为国际市场的可持续发展进一步夯实了基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2590831576","title":"汇宇制药:盐酸尼卡地平注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590831576","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590831576?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:43","pubTimestamp":1765525380,"startTime":"0","endTime":"0","summary":"汇宇制药公告称,公司近日收到国家药品监督管理局核准签发的公司产品盐酸尼卡地平注射液的《药品注册证书》。该药品注册分类为化学药品4类,批准后视同通过仿制药质量和疗效一致性评价。盐酸尼卡地平注射液临床上用于手术时异常高血压的紧急处理和高血压急症。根据米内网数据显示,2025年上半年中国城市公立医院终端盐酸尼卡地平注射液销售额约为3.06亿元。产品注册批件的取得在短期内对公司经营业绩不构成重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2590035514","title":"汇宇制药(688553)披露持股5%以上股东股份被轮候冻结的公告,12月11日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590035514","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590035514?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:40","pubTimestamp":1765464026,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘,汇宇制药报收于18.65元,较前一交易日下跌1.17%,最新总市值为79亿元。公司近日发布公告称,截至公告披露日,四川汇宇制药股份有限公司股东黄干益先生持有公司股份27,219,439股,占公司总股本的6.43%。近日,其持有的1,300,000股股份被四川省安岳县人民法院轮候冻结,占其所持股份的4.78%,占公司总股本的0.31%,冻结原因为债务合同纠纷保全。截至2025年12月10日,黄干益累计被轮候冻结股份7,650,738股,占其所持股份的28.11%,占公司总股本的1.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100042420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2586357243","title":"汇宇制药(688553.SH)拟出资1.5亿元参与设立私募基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2586357243","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586357243?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:50","pubTimestamp":1764233428,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司拟与杭州晓池私募基金管理有限公司(简称“晓池资本”)、成都光华梧桐股权投资基金管理有限公司(简称“光华梧桐”)及其他合伙人共同投资设立成都汇宇晓池生物医疗创业投资合伙企业(有限合伙),主要投资于生物医疗领域,重点聚焦管线处于临床关键中后期、具备明确商业潜力的投资标的。该私募基金初始认缴规模为4亿元,公司拟作为有限合伙人以自有资金认缴出资额1.5亿元,占初始总认缴规模出资总额的37.50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2585459069","title":"汇宇制药涨5.37%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2585459069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585459069?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:36","pubTimestamp":1763969800,"startTime":"0","endTime":"0","summary":"今日汇宇制药(688553)涨5.37%,收盘报20.0元。2025年9月3日,开源证券研究员余汝意,刘艺发布了对汇宇制药的研报《公司信息更新报告:扣非净利润稳健增长,创新+出海持续推进》,该研报对汇宇制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为72.23%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的余汝意、刘艺。汇宇制药(688553)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400013175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","161027"],"gpt_icon":0},{"id":"2585146106","title":"每周股票复盘:汇宇制药(688553)多款产品获境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2585146106","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585146106?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:52","pubTimestamp":1763844730,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,汇宇制药报收于18.98元,较上周的21.46元下跌11.56%。本周,汇宇制药11月18日盘中最高价报22.11元。公司公告汇总关于自愿披露公司产品获得境外上市许可的公告四川汇宇制药股份有限公司子公司Seacross Pharmaceuticals Ltd.近期获得巴基斯坦、英国和北马其顿药品监管机构核准,其产品普乐沙福注射液、注射用塞替派、注射用阿扎胞苷、注射用唑来膦酸浓溶液及唑来膦酸注射液取得上市许可。目前国内外尚无同类产品获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770644767446,"stockEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0732},{"period":"6month","weight":-0.136},{"period":"1year","weight":0.3218},{"period":"ytd","weight":0.0821}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13908人(较上一季度减少14.45%)","perCapita":"24700股","listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","registeredCapital":"42360万元","survey":" 四川汇宇制药股份有限公司的主营业务是肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。公司的主要产品是原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。","listedPrice":38.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}